Parkinson’s disease is one of the most common neurodegenerative disorders and it is estimated that it affects 1-2% of total world population. It is a chronic and a progressive disease, age being the primary risk factor. Basic neuropathologic finding in PD is the death of dopaminergic neurons in the nigrostriatal pathway, leading to great deficiencies in striatal dopamine supply. These processes result in the onset of notorious motor symptoms of PD: resting tremor, rigidity, bradykinesia leading to akinesia and postural instability. The main target of pharmacological approaches to treating PD is the dopaminergic system, with a main goal of reducing the intensity of motor symptoms, directly influencing the brain dopamine levels. The most common therapeutic choice during the first years of the disease is levodopa, a dopamine precursor, in a fixed combination with carbidopa. After the incidence of complications and negative effects of levodopa on the periphery increases, which happens with years of administration, the second line agents become a therapy of choice. Dopamine receptor agonists, selective monoamine oxidase-B inhibitors, catechol-O-methyltransferase inhibitors and muscarinic receptor antagonists are just some of many. Said agents are used as monotherapy or combined with levodopa and carbidopa. A link between all of them is, however, their effects are only observed in alleviation of motor and non-motor symptoms of PD; they have no effects on the causes and progression of the disease itself. In recent years, intense efforts are being invested into research and development of new therapeutic forms for PD. Genetic and stem-cell therapy are exquisite examples of new outlooks for future possibilities in treatment of neurodegenerative diseases. One of the ambitious goals of these novel approaches is implantation of new, stem-cell derived neurons into the affected area of the nigrostriatal pathway. This kind of ventures are, although very important for the future, still in the early stages of development and inapplicable in a broader perspective. Thus, pharmacotherapy and individualized patient approach in context of therapeutics administration, remain a most important pillar in life and improving life quality of patients with PD.